Low-dose aspirin might alleviate the symptoms of preeclampsia by increasing the expression of antioxidative enzymes.

Abstract

Preeclampsia (PE) is a pregnancy-related syndrome that is characterized by new onset of hypertension combined with proteinuria or end-organ dysfunction occurring after 20 weeks of pregnancy. Endothelial dysfunction is also commonly observed in patients with PE. PE remains a leading cause of maternal morbidity and mortality, resulting in ~76,000 maternal and 500,000 fetus and newborn deaths worldwide annually. The present study aimed to investigate the protective effect of aspirin in patients with PE. A PE model was established in C57/BL mice, followed by the detection of expression levels of antioxidative enzymes, including superoxide dismutase 1, catalase, periaxin and thioredoxin and AKT/mTOR signaling pathway-related proteins by performing western blotting. The concentration of these enzymes in serum samples from PE model mice was also assessed. Compared with the negative control group, the expression of these antioxidative enzymes was decreased in PE model mice (P<0.05). High-dose aspirin treatment enhanced PE-induced effects, whereas low-dose aspirin treatment partially reversed PE-induced effects (P<0.05). Moreover, the results indicated that the effects of aspirin treatment on PE might be mediated via the AKT/mTOR signaling pathway. Therefore, low-dose aspirin administration may serve as a therapeutic strategy for PE.